Meningioma of BrainNCT07418775
Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
An observational study of Meningioma of Brain and Meningioma, run by University of California, San Francisco at 1 site in United States.
Trial summary
Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Meningioma of Brain, Meningioma, Brain Tumor
- What is being tested?
- Questionnaire and Medical Record Review
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 3,000 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Jan 2026to 1 Jan 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult participants receiving care at the University of California, San Francisco who have been diagnosed with meningioma.
Who may be able to join
- Adults ≥18 years of age
- Able to speak and read English
- Diagnosed with a meningioma
Who cannot join
- Active psychiatric issues (suicidality, active psychosis, grave disability, etc.)
- Inability to consent secondary to severe neurologic deficit or psychiatric distress
- Inability to complete survey secondary to severe neurologic deficit or psychiatric distress
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California San Francisco
San Francisco, California, 94143
Zora Arum, 877-827-3222, zora.arum2@ucsf.edu
877-827-3222, cancertrials@ucsf.edu
About this study
Official title: An Investigation of Tumor Genomics, Individual Risk Factors, and External Drivers of Health to Improve Health Outcomes for Patients With Meningioma
Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.
Read the detailed description
PRIMARY OBJECTIVES:
- To assess prevalence and distribution of social and structural determinants of health (SSDH) among meningioma patients.
II. To assess disparities in SSDH among meningioma patients of different races.
OUTLINE: This is an observational study.
Participants will complete a survey and have their medical records reviewed.
- Conditions
- Meningioma of Brain, Meningioma, Brain Tumor
- Being tested
- Questionnaire, Medical Record Review
- Medical subject headings
- Meningioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireBehavioural
A questionnaire will be administered in person or online
Medical Record ReviewOther
Medical records will be reviewed for study specific data collection
| Study group | Role | What they receive |
|---|---|---|
| Participants with Meningioma | Adult patients who have been diagnosed with a meningioma will be asked to complete a one-time survey, which will take roughly 20 minutes to complete. Participants will also have medical records reviewed to capture additional data relating to the participants medical history. Receives: Behavioral: Questionnaire; Other: Medical Record Review |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identifying potential social and structural determinants of health (SSDH)
The prevalence of SSDH factors such as race and ethnicity, birthplace, relationship status, sexual orientation/gender identity, education level, socio-economic status, access to care, reproductive/menstrual history, health factors and medication use, chemical and radiation exposure, smoking history, and perceived stress for participants with meningioma will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Measured: Up to 5 years
Distribution of social and structural determinants of health
The distribution of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Measured: Up to 5 years
Identify disparities in social and structural determinants of health (SSDH)
Disparities of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start16 Jan 2026
- Primary completion1 Jan 2031 (estimated)
- Study completion1 Jan 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Meningioma of BrainStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- David Raleigh, MD, PhD, Principal investigator, University of California, San Francisco, San Francisco, California 94143
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07418775
- Sponsor's protocol ID
- 25109
- Other IDs
- NCI-2026-00576, 1U54CA302452-01
- Status last verified
- May 2026
- First submitted
- 11 Feb 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Investigation of Tumor Genomics, Individual Risk Factors, and External Drivers of Health to Improve Health Outcomes for Patients With Meningioma
- ClinicalTrials.gov ID
- NCT07418775
- Acronym / sponsor ID
- 25109
- Conditions
- Meningioma of Brain, Meningioma, Brain Tumor
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 16 Jan 2026 (actual)
- Primary completion
- 1 Jan 2031 (estimated)
- Study completion
- 1 Jan 2032 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.
Detailed description
PRIMARY OBJECTIVES:
- To assess prevalence and distribution of social and structural determinants of health (SSDH) among meningioma patients.
II. To assess disparities in SSDH among meningioma patients of different races.
OUTLINE: This is an observational study.
Participants will complete a survey and have their medical records reviewed.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants with Meningioma | – | Behavioral: Questionnaire, Other: Medical Record ReviewAdult patients who have been diagnosed with a meningioma will be asked to complete a one-time survey, which will take roughly 20 minutes to complete. Participants will also have medical records reviewed to capture additional data relating to the participants medical history. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult participants receiving care at the University of California, San Francisco who have been diagnosed with meningioma.
Key inclusion criteria (3 listed)
- Adults ≥18 years of age
- Able to speak and read English
- Diagnosed with a meningioma
Key exclusion criteria (3 listed)
- Active psychiatric issues (suicidality, active psychosis, grave disability, etc.)
- Inability to consent secondary to severe neurologic deficit or psychiatric distress
- Inability to complete survey secondary to severe neurologic deficit or psychiatric distress
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireA questionnaire will be administered in person or online | Behavioural | Participants with Meningioma |
| Medical Record ReviewMedical records will be reviewed for study specific data collection | Other | Participants with Meningioma |
Primary outcome
Identifying potential social and structural determinants of health (SSDH)
Time frame: Up to 5 years
The prevalence of SSDH factors such as race and ethnicity, birthplace, relationship status, sexual orientation/gender identity, education level, socio-economic status, access to care, reproductive/menstrual history, health factors and medication use, chemical and radiation exposure, smoking history, and perceived stress for participants with meningioma will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Distribution of social and structural determinants of health
Time frame: Up to 5 years
The distribution of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Identify disparities in social and structural determinants of health (SSDH)
Time frame: Up to 5 years
Disparities of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Individual participant dataSharing planned: No
Related trials for Meningioma of Brain
RecruitingPhase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
RecruitingPhase 4
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
CNS Tumors, Meningioma
RecruitingPhase 2
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Meningioma
Active, not recruitingPhase 2
Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy
Radiation of Neurocranial Region
RecruitingPhase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Central Nervous System Neoplasms, Glioblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Raleigh, MD, PhD principal investigator
University of California, San Francisco, San Francisco, California 94143
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Meningioma of Brain and Meningioma, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zora Arum (877-827-3222, zora.arum2@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identifying potential social and structural determinants of health (SSDH) (time frame: Up to 5 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.